Product Description: HJM-561 is a potent, selective, orally bioavailable EGFR PROTAC. HJM-561 overcomes osimertinib (HY-15772)-resistant EGFR triple mutations and has anti-tumor activity[1].
Formula: C45H51ClN9O5P
References: [1]Du Y, et al. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations. Mol Cancer Ther. 2022 Jul 5;21(7):1060-1066.
CAS Number: 2570251-68-0
Molecular Weight: 864.37
Compound Purity: 98.64
Research Area: Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: PROTACs